CN103974934B - 使用sirt2调节剂的治疗方法 - Google Patents

使用sirt2调节剂的治疗方法 Download PDF

Info

Publication number
CN103974934B
CN103974934B CN201280059788.2A CN201280059788A CN103974934B CN 103974934 B CN103974934 B CN 103974934B CN 201280059788 A CN201280059788 A CN 201280059788A CN 103974934 B CN103974934 B CN 103974934B
Authority
CN
China
Prior art keywords
sirt2
groups
group
activity
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280059788.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103974934A (zh
Inventor
林合宁
何彬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Priority to CN201910002021.XA priority Critical patent/CN110143900B/zh
Publication of CN103974934A publication Critical patent/CN103974934A/zh
Application granted granted Critical
Publication of CN103974934B publication Critical patent/CN103974934B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/42—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280059788.2A 2011-10-07 2012-10-05 使用sirt2调节剂的治疗方法 Expired - Fee Related CN103974934B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910002021.XA CN110143900B (zh) 2011-10-07 2012-10-05 使用sirt2调节剂的治疗方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161544452P 2011-10-07 2011-10-07
US61/544,452 2011-10-07
PCT/US2012/058846 WO2013052727A1 (en) 2011-10-07 2012-10-05 Methods of treatment using modulators of sirt2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910002021.XA Division CN110143900B (zh) 2011-10-07 2012-10-05 使用sirt2调节剂的治疗方法

Publications (2)

Publication Number Publication Date
CN103974934A CN103974934A (zh) 2014-08-06
CN103974934B true CN103974934B (zh) 2019-07-23

Family

ID=48044173

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280059788.2A Expired - Fee Related CN103974934B (zh) 2011-10-07 2012-10-05 使用sirt2调节剂的治疗方法
CN201910002021.XA Expired - Fee Related CN110143900B (zh) 2011-10-07 2012-10-05 使用sirt2调节剂的治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910002021.XA Expired - Fee Related CN110143900B (zh) 2011-10-07 2012-10-05 使用sirt2调节剂的治疗方法

Country Status (6)

Country Link
US (2) US9359293B2 (enExample)
EP (1) EP2763962B1 (enExample)
CN (2) CN103974934B (enExample)
ES (1) ES2773266T3 (enExample)
IN (1) IN2014DN03077A (enExample)
WO (1) WO2013052727A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103974934B (zh) * 2011-10-07 2019-07-23 康奈尔大学 使用sirt2调节剂的治疗方法
WO2014149196A1 (en) * 2013-03-22 2014-09-25 University Of Florida Research Foundation, Inc. Polymer nanocomposites for early diagnosis of diseases
US10556878B2 (en) * 2013-06-06 2020-02-11 Cornell University Thiourea compounds and their use as inhibitors of Sirt2 or Sirt5
WO2018144864A1 (en) * 2017-02-03 2018-08-09 The Mclean Hospital Corporation Methods for manipulating cell fate
CN110551048B (zh) * 2018-06-04 2021-08-10 中国科学院上海药物研究所 一类sirt2抑制剂、其制备方法及用途
US12161639B2 (en) 2018-07-17 2024-12-10 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating PACS1 and PACS2 syndromes
CN114315670B (zh) * 2022-01-19 2024-03-29 贵州医科大学 一种sirt2/hdac6双靶标抑制剂及其应用
CN116178340B (zh) * 2023-04-28 2023-08-18 细胞生态海河实验室 一种protac化合物、制备方法及药物组合物
WO2026125700A1 (de) * 2024-12-13 2026-06-18 Heinrich-Heine-Universität Düsseldorf Zielgerichtete therapie von krebs durch pharmakologische aktivierung von mtor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1898227A (zh) * 2003-12-22 2007-01-17 安斯泰来制药有限公司 作为前列腺素e2激动剂或拮抗剂的鸟氨酸衍生物
US20070021434A1 (en) * 2005-06-24 2007-01-25 Migenix Inc. Non-nucleoside anti-hepacivirus agents and uses thereof
US20080171783A1 (en) * 2006-12-28 2008-07-17 Migenix Inc. Compositions and methods for treating hyperproliferative disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
CN103974934B (zh) * 2011-10-07 2019-07-23 康奈尔大学 使用sirt2调节剂的治疗方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1898227A (zh) * 2003-12-22 2007-01-17 安斯泰来制药有限公司 作为前列腺素e2激动剂或拮抗剂的鸟氨酸衍生物
US20070021434A1 (en) * 2005-06-24 2007-01-25 Migenix Inc. Non-nucleoside anti-hepacivirus agents and uses thereof
US20080171783A1 (en) * 2006-12-28 2008-07-17 Migenix Inc. Compositions and methods for treating hyperproliferative disease

Also Published As

Publication number Publication date
EP2763962A1 (en) 2014-08-13
EP2763962B1 (en) 2019-12-04
US20140249216A1 (en) 2014-09-04
ES2773266T3 (es) 2020-07-10
CN103974934A (zh) 2014-08-06
IN2014DN03077A (enExample) 2015-05-15
US20160279091A1 (en) 2016-09-29
US9359293B2 (en) 2016-06-07
CN110143900A (zh) 2019-08-20
US9572789B2 (en) 2017-02-21
CN110143900B (zh) 2021-08-03
WO2013052727A1 (en) 2013-04-11
EP2763962A4 (en) 2015-08-19

Similar Documents

Publication Publication Date Title
CN110143900B (zh) 使用sirt2调节剂的治疗方法
US9872919B2 (en) Prodrugs for selective anticancer therapy
CN101723896B (zh) 酪氨酸衍生物类组蛋白去乙酰化酶抑制剂及其应用
RU2577861C2 (ru) N-гидрокси-бензамиды для лечения рака
Anh et al. Exploration of certain 1, 3-oxazole-and 1, 3-thiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents
WO2021115188A1 (zh) 一种组蛋白去乙酰化酶、蛋白酶体双靶点抑制剂及其制备方法和应用
Li et al. Novel pyrrolo [2, 1-c][1, 4] benzodiazepine-3, 11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo
JP4348014B2 (ja) Ｎ−アリールスルホニルアミノ酸オメガ−アミド
CN102180826B (zh) 含α氨基酸结构的组蛋白去乙酰化酶抑制剂及其用途
US10072282B2 (en) Modulators for SIRT6 and assays for screening same
US10556878B2 (en) Thiourea compounds and their use as inhibitors of Sirt2 or Sirt5
CN103553957B (zh) 含有组蛋白去乙酰化酶抑制活性的秋水仙碱衍生物及制备方法和用途
Shang et al. Novel 3-phenylpropane-1, 2-diamine derivates as inhibitors of aminopeptidase N (APN)
CN111205244A (zh) 噻唑并环类化合物、其制备方法、中间体和应用
Shang et al. Design, synthesis and SAR studies of tripeptide analogs with the scaffold 3-phenylpropane-1, 2-diamine as aminopeptidase N/CD13 inhibitors
CN102276495B (zh) 3-氨基-2-羟基苯丙酸类金属蛋白酶抑制剂及其制备方法和应用
Gredičak et al. Cyclic enediyne–amino acid chimeras as new aminopeptidase N inhibitors
CN102010425A (zh) 1,4-二硫-7-氮杂螺[4,4]壬烷-8-羧酸衍生物类组蛋白去乙酰化酶抑制剂及其应用
Vaughn Design, Synthesis, And Biological Evaluation of Small Molecules HDAC8 Inhibitors for Use in Acute Kidney Injury (AKI)
EP3381898A1 (en) Symmetrical tris-aryl-amide derivatives and their use as anti-heparanase

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190723

CF01 Termination of patent right due to non-payment of annual fee